Drug Profile
VIS 624
Alternative Names: VIS624Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Visterra
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Multiple myeloma in USA (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
- 31 Aug 2018 Visterra has been acquired by Otsuka Pharmaceutical